

## **Product** Data Sheet

Molecular Weight:

 $C_{29}H_{28}N_{2}O_{7}$ 516.54

Target:

PPAR

Pathway:

Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor

Storage:

Please store the product under the recommended conditions in the Certificate of  $\,$ 

Analysis.

O NO O

## **BIOLOGICAL ACTIVITY**

Description

Muraglitazar is a PPAR  $\alpha/\gamma$  dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPAR $\alpha$  (EC<sub>50</sub> = 320 nM) and PPAR $\gamma$ (EC<sub>50</sub> = 110 nM)<sup>[1]</sup>.

## **REFERENCES**

[1]. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27(8):1181-1195.

[2]. Cox SL. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc). 2005;41(9):579-587.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

**Proteins** 

Inhibitors